Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30636388 | 1.00 | GRM2 (0.33) | GRM2HDAC1HDAC8HDAC6PDPK1 | |
| SCHEMBL29874252 | 0.95 | PDPK1 (0.33) | GRM2HDAC1HDAC8HDAC6PDPK1 | |
| SCHEMBL26933292 | 0.83 | GRM2 (0.35) | GRM2HDAC1HDAC8HDAC6PDPK1 | |
| SCHEMBL30636312 | 0.83 | GRM2 (0.35) | GRM2HDAC1HDAC8HDAC6PDPK1 | |
| SCHEMBL26933099 | 0.81 | PDPK1 (0.32) | GRM2HDAC1HDAC8HDAC6PDPK1 | |
| SCHEMBL26933027 | 0.80 | SSTR4 (0.35) | GRM2HDAC1HDAC8HDAC6SYK | |
| SCHEMBL26933510 | 0.79 | GRM2 (0.34) | GRM2HDAC1HDAC8HDAC6PDPK1 | |
| SCHEMBL26933098 | 0.79 | — | — | |
| SCHEMBL29874548 | 0.77 | GRM2 (0.35) | GRM2HDAC1HDAC8HDAC6PDPK1 | |
| SCHEMBL26933637 | 0.77 | GABRA1 (0.37) | GRM2HDAC1HDAC8HDAC6SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313951-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| US-11845730-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2023-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845730-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | TRPV1, TRPV3, TRPV2 | GRM2 657/4885HDAC1 989/4885HDAC8 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.